Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

107 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction: Pembrolizumab, radiotherapy, and an immunomodulatory five-drug cocktail in pretreated patients with persistent, recurrent, or metastatic cervical or endometrial carcinoma: Results of the phase II PRIMMO study.
De Jaeghere EA, Tuyaerts S, Van Nufel AMT, Belmans A, Bogaerts K, Baiden-Amissah R, Lippens L, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Denys HG. De Jaeghere EA, et al. Among authors: van dam pa. Cancer Immunol Immunother. 2024 Dec 30;74(1):32. doi: 10.1007/s00262-024-03873-5. Cancer Immunol Immunother. 2024. PMID: 39738642 Free PMC article. No abstract available.
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
De Jaeghere EA, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel AMT, Baiden-Amissah R, Vuylsteke P, Henry S, Trinh XB, van Dam PA, Aspeslagh S, De Caluwé A, Naert E, Lambrechts D, Hendrix A, De Wever O, Van de Vijver KK, Amant F, Vandecasteele K, Verhasselt B, Denys HG. De Jaeghere EA, et al. Among authors: van dam pa. Gynecol Oncol. 2024 Dec;191:275-286. doi: 10.1016/j.ygyno.2024.10.020. Epub 2024 Nov 7. Gynecol Oncol. 2024. PMID: 39515198 Clinical Trial.
An open-label, single-arm, prospective, multi-center, tandem two-stage designed phase II study to evaluate the efficacy of fulvestrant in women with recurrent/metastatic estrogen receptor-positive gynecological malignancies (FUCHSia study).
Trozzi R, Tuyaerts S, Annibali D, Herreros Pomares A, Boog L, Van Dam P, Leunen K, Deroose C, Trum H, Amant F. Trozzi R, et al. Int J Gynecol Cancer. 2024 Aug 5;34(8):1217-1224. doi: 10.1136/ijgc-2023-005229. Int J Gynecol Cancer. 2024. PMID: 38724237 Clinical Trial.
Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
Aronson SL, Walker C, Thijssen B, van de Vijver KK, Horlings HM, Sanders J, Alkemade M, Koole SN, Lopez-Yurda M, Lok CAR; OVHIPEC-1 Study Group; Rottenberg S, van Rheenen J, Sonke GS, van Driel WJ, Kester LA, Hahn K. Aronson SL, et al. Br J Cancer. 2024 Aug;131(3):565-576. doi: 10.1038/s41416-024-02731-6. Epub 2024 Jun 12. Br J Cancer. 2024. PMID: 38866963 Free article.
Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy.
Despierre E, Vergote I, Anderson R, Coens C, Katsaros D, Hirsch FR, Boeckx B, Varella-Garcia M, Ferrero A, Ray-Coquard I, Berns EM, Casado A, Lambrechts D, Jimeno A; European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group (EORTC-GCG); Groupe d’Investigateurs Nationaux pour les Etudes des Cancers de l’Ovaire (GINECO); Austrian Arbeitsgemeinschaft für Gynäkologische Onkologie (A-AGO); National Cancer Research Institute (NCRI); Australia New Zealand Gynaecological Oncology Group (ANZGOG); Mario Negri Gynecologic Oncology group (MaNGO). Despierre E, et al. Target Oncol. 2015 Dec;10(4):583-96. doi: 10.1007/s11523-015-0369-6. Target Oncol. 2015. PMID: 26004768 Free PMC article. Clinical Trial.
Higher relative survival in breast cancer patients treated in certified and high-volume breast cancer centres - A population-based study in Belgium.
Leroy R, Silversmit G, Bourgeois J, De Gendt C, Savoye I, Verbeeck J, Van Damme N, Stordeur S, Canon JL, Carly B, Cusumano PG, de Azambuja E, De Visschere P, Decloedt J, Desreux J, Duhoux FP, Taylor D, van Dam P, Vanhoutte I, Veldeman L, Wildiers H. Leroy R, et al. Eur J Cancer. 2024 Oct;210:114232. doi: 10.1016/j.ejca.2024.114232. Epub 2024 Jul 20. Eur J Cancer. 2024. PMID: 39236426
Long-term effects of the COVID-19 pandemic for patients with cancer.
Debie Y, Palte Z, Salman H, Verbruggen L, Vanhoutte G, Chhajlani S, Raats S, Roelant E, Vandamme T, Peeters M, van Dam PA. Debie Y, et al. Among authors: van dam pa. Qual Life Res. 2024 Oct;33(10):2845-2853. doi: 10.1007/s11136-024-03726-9. Epub 2024 Jul 3. Qual Life Res. 2024. PMID: 38961007 Free PMC article.
Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Aronson SL, et al. Among authors: van dam pa. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. Lancet Oncol. 2023. PMID: 37708912 Clinical Trial.
107 results